ERP44 could serve as a bridge mediating prognosis and immunity for glioma via single-cell and bulk RNA-sequencing

• Published in: Gene 2025-01, Vol.933, p.148963, Article 148963
• Main Authors: Ji, Xiang, Chen, Zhenglou, Wang, Yunjiang, Huo, Xuqi, Liang, Xiaodong, Wang, Hongsheng, Xu, Min
• Format: Article
• Language: English
• Subjects: Biomarker; Biomarkers, Tumor - genetics; Brain Neoplasms - genetics; Brain Neoplasms - immunology; ERP44; Female; Gene Expression Regulation, Neoplastic; Glioma; Glioma - genetics; Glioma - immunology; Glioma - pathology; Humans; Immunity; Male; Membrane Proteins - genetics; Membrane Proteins - metabolism; Middle Aged; Molecular Chaperones - genetics; Molecular Chaperones - metabolism; Prognosis; Proteomics - methods; Sequence Analysis, RNA; Single-Cell Analysis - methods
• ISSN: 0378-1119; 1879-0038; 1879-0038
• DOI: 10.1016/j.gene.2024.148963

•We firstly integrated proteomics, bulk, as well as single-cell RNA-sequencing to study the possible functions of ERP44 in glioma.•The expression of ERP44 was markedly higher in glioma tissues compared with normal tissues by online datasets and experiments.•ERP44 was found to be an oncogenic gene in gliomas, serving as a bridge mediating prognosis and immunity. There was evidence that ERP44 played vital roles in a variety of cancers. However, currently, ERP44 was rarely mentioned in gliomas. Therefore, we firstly integrated proteomics, bulk, as well as single-cell RNA-sequencing (scRNA-seq) to study the possible functions of ERP44 in glioma patients. From online databases, we obtained bulk RNA-seq, scRNA-seq, and proteomic data of ERP44 in gliomas and verified the expression of ERP44 by qRT-PCR. Then, the Noman diagram, gene set enrichment analysis (GSEA), and univariate/multivariate Cox regression analysis were all carried out in turn. Further discussions were also conducted regarding tumor immunity and ERP44 expression. ERP44 in glioma tissues was found to be considerably higher than that in normal tissues (P